Stock in AVEO Oncology plummeted Tuesday after documents posted to the website of the U.S. Food and Drug Administration indicated that the company may need another trial of the kidney cancer drug candidate for which it was hoping to get approval on Thursday.
http://www.bizjournals.com/boston/blog/bioflash/2013/04/fda-may-ask-for-new-trial-of-aveos.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_37+%28Physician+Practices+Industry+News%29
http://www.bizjournals.com/boston/blog/bioflash/2013/04/fda-may-ask-for-new-trial-of-aveos.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_37+%28Physician+Practices+Industry+News%29
No comments:
Post a Comment